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ABSTRACT
Objectives: The aim is to compare the hormonal status and anti-müllerian hormone (AMH) levels of patients who have 
different polycystic ovary syndrome (PCOS) phenotypes, polycystic ovarian morphology (PCOM) and healthy women. 
Material and methods: A total of 350 PCOS women, 71 women with PCOM and 79 healthy women with normal ovar-
ian morphology (NOM) were observed. PCOS patients were divided into groups according to the phenotypes. Phenotype 
A- characterized by anovulation, hyperandrogenism and PCOM; phenotype B- defined as anovulation, hyperandrogenism; 
Phenotype C- identified as hyperandrogenism and PCOM; Phenotype D- outlined as anovulation and PCOM. AMH levels 
were compared for each group. 
Results: Among 350 PCOS patients the highest number belonged to phenotype A (n = 117, 33.4%). The rest were distrub-
uted as follows: phenotype B (n = 89, 25.4%), phenotype C (n = 72, 20.6%), phenotype D (n = 72, 20.6%). Phenotype A  
(9.17 ± 4.56) had the highest mean AMH levels in our study. Comparison of AMH levels showed a statistically significant 
difference between phenotypes A and D. There was a statistically significant difference on comparison of AMH between 
NOM, PCOM and all PCOS phenotypes.
Conclusions: Phenotype A is the most serious form of PCOS and these patients has all three features which are hyperan-
drogenism, anovulation and ultrasound findings of polycystic ovary (PCO). AMH reflects the severity of PCOS and patients 
with Phenotype A have higher AMH levels. 
Key words: polycystic ovary syndrome; phenotype; polycystic ovarian morphology; anti müllerian hormone; hyperan-
drogenism
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INTRODUCTION
Polycystic ovary syndrome (PCOS) is the highest prev-
alent hormonal disturbance among reproductive age 
women. PCOS affects 4–21% of women worldwide [1]. The 
symptoms of PCOS include menstrual irregularity, clinical or 
biochemical hyperandrogenism findings and obesity. The 
definition and diagnosis of PCOS have long been debated. 
In 1990, National Institute of Child Health and Human Dis-
ease (NICHD) congress participants agreed that the major 
diagnostic criteria for PCOS should include hyperandrogen-
ism and menstrual dysfunction and the exclusion of other 
endocrine disorders [2]. On the other hand, the ultrasound 
has been widely used in Europe for the diagnosis of PCOS [3]. 
In 2003, a meeting was held in Rotterdam to provide con-
sensus for PCOS diagnostic criteria. According to the Rot-
terdam classification in 2003, when two or more of the fol-
lowing aspects are existent, PCOS can be determined: ano-
vulation, hypernadrogenism and polycystic ovaries [4, 5]. 
In the Rotterdam consensus conference, it was decided 
that the following sonographic descriptions of polycystic 
ovarian morphology (PCOM) should be included: enlarged 
volume of the ovaries (≥ 10 cm3) or either ≥ 12 follicles per 
ovary sized between 2–9 mm [5]. The Rotterdam consensus 
decisions generated the possibility of four phenotypes of 
PCOS. For the diagnosis of PCOS, only the presence of PCOM 
on ultrasound is not acceptable [5]. In addition, according 
to Azziz, the definition of PCOM should be made very care-
fully and in the abscence of any other sign or symptom of 
PCOS, PCOM should not be accepted as PCOS [6]. The clinical 
significance of the polycystic presentation of the ovaries on 
ultrasound still continues to be unclear. Indeed, signs and 
symptoms are heterogeneously combined in each affected 
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woman. There is a wide spectrum of clinical and biochemical 
differences between PCOS patients [7]. The classification 
of such a varied pathology has presented dilemma for the 
gynecologist and therefore set up the potentiality of four 
different phenotypes of PCOS.
According to the Rotterdam criteria, there are four major 
phenotypes defined on the symptoms and clinical find-
ings of PCOS. In patients with PCOS, phenotypes should 
be determined by following the correct algorithm in or-
der to obtain healthier results [8]. Phenotype A- identified 
by anovulation, hyperandrogenism and polycystic ovaries 
on ultrasound; phenotype B- identified with anovulation, 
hyperandrogenism; Phenotype C- defined as hyperandro-
genism and polycystic ovaries on ultrasound; Phenotype 
D- diagnosed as anovulation, polycystic ovaries on ultra-
sound [5]. The utmost serious form of PCOS is phenotype 
A and these patients have all three features which are hy-
perandrogenism, anovulation and ultrasound findings of 
polycystic ovary (PCO). 
Anti-müllerian hormone (AMH), a polypeptide, which is 
synthesized from the granulosa cells of the preantral and 
early developing antral follicles, belongs to the transforming 
growth factor beta superfamily [9]. The major physiological 
act of AMH in the ovary is the prevention of primordial fol-
licles recruitment and the regulation of FSH secretion in the 
early follicular phase [10]. Antral follicule count is associated 
with serum AMH levels. PCOS patients display an elevated 
number of antral follicles; therefore AMH levels are 2–3-fold 
augmented in PCOS patients [11–14]. As a result of a recent 
study in animals, AMH acted a significant part in the patho-
genesis of PCOS starting from intrauterine life [15]. Pigny et 
al. [16] found that there was a significant relation between 
follicle count and AMH values in PCOS patients. Although 
the AMH is elevated in patients with PCOS, it is still not 
recommended to use serum AMH measurement alone to 
diagnose PCOS [17, 18]. Since the phenotypes of polycys-
tic ovary syndrome has different clinical and biochemical 
features, it has been claimed that the serum levels of AMH 
may vary between these phenotypes. In a recent study it is 
shown that serum AMH levels were higher in hyperandro-
genic PCOS phenotypes and in PCOS patients that have all 
three Rotterdam criterias [19]. 
PCOS is a heterogenous clinical condition and the four 
major phenotypes show different clinical presentations. In-
vestigation of the disparities between women with different 
phenotypes of PCOS, women with polycystic appearance 
only (PCOM) and healthy women with normal ovarian mor-
phology (NOM) enhance the understanding of the patho-
physiology of PCOS. Our aim is to observe and compare the 
hormonal status and AMH levels of patients with different 
PCOS phenotypes, PCOM and healthy women with normal 
ovarian morphology. Our hypothesis is that PCOS pheno-
types with anovulation may produce elevated levels of AMH 
compared to phenotypes with regular ovulatory cycles or 
only polycystic ovarian morphology (PCOM) on ultrasound. 
MATERIAL AND METHODS
The indicated retrospective study was planned in the 
Obstetrics and Gynecology Clinic of Dokuz Eylul University 
Hospital, Faculty of Medicine, Izmir/Turkey, during the time 
period of January 2012 to July 2015. The research customs 
was authorized by Dokuz Eylul University local review board. 
Enlightened approval form was collected from all participi-
tants of the study. In date range we specified, 1871 patients 
who underwent serum anti-mullerian hormone tests in our 
hospital were identified by scanning the database and pa-
tient files of the hospital. The flow chart of the study is shown 
in Figure 1. A total of 500 eligiable patients were recruited, 
including 350 PCOS women, 71 women with polycystic 
ovarian morphology on ultrasound (PCOM) and 79 healthy 
women with normal ovarian morphology (NOM) which 
were suitable for our study. PCOS patients were divided 
into groups according to the phenotypes defined in Rot-
terdam criteria [5]. 
In our hospital, anamnesis, gynecological examination 
and pelvic ultrasonography are standard practice for all pa-
tients who apply to the gynecology outpatient clinic. These 
history and examination findings were documented from 
hospital database and patients’ files. Calculations were done 
for Ferriman-Gallwey score (FGS) and Body Mass Index (BMI). 
Hirsutism was represented when FGS was ≥ 8. PCOS diagno-
sis was made according to the Rotterdam Consensus [5]. The 
polycystic ovarian morphology was described as reported 
by the Rotterdam criteria [5, 6]. All healthy women had 
regular monthly menstrual cycles and initial examination 
by transvaginal ultrasound showed normal uteruses and 
ovaries. Exclusion principles were as follows; age up 35 years, 
Figure 1. Flow chart of the study; PCOS — polycystic ovary 
syndrome; PCOM — polycystic ovarian morphology on ultrasound; 
NOM — normal ovarian morphology
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ovarian surgery history, thyroid disease, systemic diseases, 
hyperprolactinemia, congenital adrenal hyperplasia, or drug 
usage effecting androgen metabolism, glucose/insulin me-
tabolism and hypothalamus-hypophysis-ovary axis. In addi-
tion, the women who had used contraceptives or hormonal 
treatment up to 6 months were also considered as exclusion 
factors. If any existence of lesions, cysts or follicles greater 
than 10mm on the ovaries, it was accepted as an exclusion 
feature. Weight and height were measured in the initial 
check-up. The formula weight (kg)/height (m)2 was used to 
analyze BMI. Biochemical and hormonal assesments were 
done for anti-müllerian hormone (AMH), androstenodione, 
thyroid stimulating hormone (TSH), luteinizing hormone 
(LH), total testosterone, follicle stimulating hormone (FSH), 
sex hormone binding globulin (SHBG), prolactin (PRL), in-
sulin and fasting plasma glucose. Homeostatic model of 
insulin resistance (HOMA-IR) was used to evaluate normal 
insulin sensitivity. Determination of HOMA-IR was by the 
equation: HOMA-IR = fasting blood glucose (mg/dL) X fast-
ing insulin (mIU/mL)/405. Definition of insulin resistance was 
made in the presence of HOMA-IR being equal or greater 
than 2.5. Formula for the calculation of free androgen index 
(FAI) was 100x (Total testosterone/SHBG). Between the sec-
ond and fifth days of the menstrual cycle, patients’ blood 
samples were collected in the morning following 8 hours 
fasting. For amenorrhoeic women, pregnancy was elimi-
nated then, medroxyprogesterone acetate (TARLUSAL; Deva 
Holding A.S¸. Istanbul, Turkey) was initiated 5 mg twice a day 
for a 5 day period to promote uterine bleeding. 
The commercial kit as reported by the manufacturer’s 
guidance depend on the settlements of the competitive 
enzyme linked immunosorbent assay (ELISA) approach 
(catalog number: CSB-E12756h, CUSABIO Biotech Co., USA) 
was used to evaluate serum anti-müllerian hormone (AMH). 
A basic curve of known concentration (0, 0.375, 1.31, 4.69, 
28.12, and 150 ng/mL) of AMH was certified and the con-
centration of analyte in the fragments was adjusted corre-
spondingly. The sensitivity of the ELISA assays of AMH was 
0.375 ng/mL; the detection range was 0.375–150 ng/mL and 
intraassay coefficient of variation was < 10%, and interassay 
coefficient of variation was < 15%.
Statistics are demonstrated as mean ± standard devia-
tion except elseways declared. Calculations were done by 
the program Statistical Program for Social Sciences (SPSS) 
version 16. (SPSS, Chicago, IL). To check for the homogeneity 
of the study group, the Kolmogorov Smirnov test was con-
ducted. Continuous variables (normally distributed) were 
compared by one-way ANOVA (> 2 groups) and then Bon-
ferroni test was used for post hoc comparison. Tamhane’s 
test was performed for continous variables that were not 
following normal distribution. P < 0.05 was accepted as the 
level of significance.
RESULTS
An overall of 500 women’s results were evaluated. 
350 PCOS patients, 71 women with polycystic ovarian mor-
phology on ultrasound (PCOM) and 79 healthy women with 
normal ovarian morphology (NOM) were assessed. Among 
the 350 PCOS patients the highest number of patients be-
longed to phenotype A (n = 117, 33.4%). The rest were distrub-
uted as follows: phenotype B (n = 89, 25.4 %), phenotype C 
(n = 72, 20.6%), phenotype D (n = 72, 20.6%). A comparison 
of the demographic and hormonal status of NOM, PCOM 
and PCOS phenotypes is shown in Table 1. The mean BMIs 
of all groups were similar and the mean BMI of groups were 
less than 25 kg/m2. Comparison of the LH/FSH ratio showed 
that all PCOS phenotypes were found to be statistically 
similar. In fact, there was a statistically significant difference 
Table 1. Comparison of demographic and hormonal status of NOM, PCOM and PCOS phenotypes










(n = 72) P
Age [years] 24.05 ± 4.59 24.86 ± 4.17 23.54 ± 4.15 23.99 ± 4.35 23.40 ± 4.84 24.81 ± 5.05 NS
BMI [kg/m2] 24.70 ± 3.35 24.93 ± 3.49 24.77 ± 4.77 23.02 ± 4.71 24.03 ± 4.48 23.06 ± 4.11 NS
LH/FSH ratio 1.01 ± 0.42 1.11 ± 0.56 1.70 ± 1.08 1.84 ± 1.49 1.44 ± 0.72 1.71 ± 0.95 < 0.001*, **
AMH [ng/mL] 3.65 ± 2.42 2.99 ± 2.00 9.17 ± 4.56 8.15 ± 4.85 7.30 ± 4.13 6.18 ± 5.46 < 0.001*, **,a
SHBG [nmol/L] 67.76 ± 24.55 69.52 ± 23.29 42.18 ± 26.02 46.44 ± 24.75 44.34 ± 38.81 55.73 ± 30.81 < 0.001a, b, c
Androstenodione [ng/mL] 1.68 ± 1.05 1.60 ± 0.93 6.09 ± 5.14 4.56 ± 4.04 4.76 ± 3.73 1.95 ± 0.60 < 0.001b, c, d
FAI 1.48 ± 0.70 1.43 ± 0.66 7.28 ± 5.37 6.14 ± 4.92 6.81 ± 5.65 3.48 ± 3.50 < 0.001*, **, e
Total testosterone [ng/dL] 0.90 ± 0.32 0.90 ± 0.31 2.15 ± 0.75 1.97 ± 0.60 1.87 ± 0.66 1.29 ± 0.40 < 0.001 *, **, e
HOMA-IR 1.60 ± 1.67 1.20 ± 1.29 2.91 ± 2.31 2.63 ± 2.14 2.70 ± 2.35 2.75 ± 2.20 < 0.001*, **
*Significant difference in NOM and PCOS A, PCOS B, PCOS C, PCOS D; **Significant difference in PCOM and PCOS A, PCOS B, PCOS C, PCOS D; aSignificant difference in 
PCOS A vs. PCOS D; bSignificant difference in NOM vs. PCOS A, PCOS B, PCOS C; cSignificant difference in PCOM vs. PCOS A, PCOS B, PCOS C; dSignificant difference in 
PCOS D vs. PCOS A, PCOS B, PCOS C; eSignificant difference in PCOS D vs. PCOS A, PCOS B, PCOS C, NOM, PCOM; BMI — body mass index; LH — luteinizing hormone; 
FSH — follicle stimulating hormone; Total T — total testosterone; FAI — free androgen ındex; AMH — antimüllerian hormone; HOMA-IR — homeostatic model for 
assessment of insulin resistance; NS — nonsignificant; *p < 0.05 is statistically significant. One-way ANOVA test
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between PCOM, NOM and all PCOS phenotypes in terms of 
the LH/FSH ratio (p < 0.001). The mean highest AMH levels 
were in phenotype A (9.17 ± 4.56 ng/mL) which was fol-
lowed by phenotype B (8.15 ± 4.85 ng/mL), phenotype C 
(7.30 ± 4.13 ng/mL), and phenotype D (6.18 ± 5.46 ng/mL). 
Comparison of AMH levels showed a statistically significant 
difference between PCOS phenotypes A and D. Table 2 dem-
onstrates the AMH levels of each group. There was a statisti-
cally significant difference on comparison of AMH between 
NOM, PCOM and all PCOS phenotypes (Fig. 2). A graphic of 
free androgen index is shown in Figure 3. In the comparison 
of HOMA-IR, there was no statistically significant difference 
between PCOS phenotypes. HOMA-IR showed a statistically 
significant difference between PCOM and all phenotypes of 
PCOS patients. NOM participants showed markedly lower 
HOMA-IR levels compared to all PCOS phenotypes (Fig. 4).
DISCUSSION
We investigated the clinical, hormonal and AMH levels 
and this study maintains knowledge on the diversity in these 
factors among the four phenotypes of PCOS according to 
the Rotterdam criteria [5], PCOM and healthy women with 
normal menstrual cycle. Mostly, AMH is produced from the 
small antral follicles and it’s levels in circulation resemble to 
total antral follicle count , granulosa cell action and ovar-
ian volume [20]. Our research supported previous studies in 
terms of high serum AMH levels in PCOS women compared 
to healthy ones and women with polycystic ovarian mor-
phology only [14, 16, 19–21]. Ovulatory disfunctions in PCOS 
are generated by two mechanisms [22]. Firstly, there is an in-
creased early follicular growth which results in an increased 
number of follicles. Secondly, there is an abnormal pick of 
dominant follicle from this increased follicular pool, leading 
to follicular cessation [22]. It is also known that the excess 
AMH origination by polycystic ovaries is an outcome of the 
increased follicle number [22]. Bhide et al. [23] suggested 
that for the assesment of antral follicle pool, AMH is a good 
tool because serum AMH concentrations have a powerful link 
with the antral follicle count (AFC). Although AMH is a good 
indicator in testing ovarian reserve, there is not enough 
data to determine a cut off value in PCOS diagnosis and dif-
Table 2. AMH levels of groups
Phenotype OA HA PCO Frequency [%] AMH [ng/mL]
A + + + % 23.4 (n = 117) 9.17 ± 4.56
B + + – %17.8 (n = 89) 8.15 ± 4.85
C – + + %14.4 (n = 72) 7.30 ± 4.13
D + – + %14.4 (n = 72) 6.18 ± 5.46
PCOM – – + %14.2 (n = 71) 2.99 ± 2.00
NOM – – – %15.8 (n = 79) 3.65 ± 2.42
OA — oligoanovulation; HA — hyperandrogenism; PCO — polycystic 
ovary appearance; AMH — anti müllerian hormone; PCOM; polycystic 
ovarian morphology; NOM — normal ovarian morphology
NOM vs PCOM p = 0.65
NOM vs PCOS phenotype D p = 0.007
NOM vs PCOS phenotype A,B,C p < 0.001
PCOM vs PCOS all phenotypes p < 0.001
PCOS A vs B p = 0.997
PCOS A vs C p = 0.968
PCOS A vs D p = 0.002
PCOS B vs C p = 0.663
PCOS B vs D p = 1.0
PCOS C vs D p = 0.442
Figure 2. Mean values of AMH for PCOS phenotypes, PCOM and 
NOM; NOM — normal ovarian morphology; PCOM — polycystic 
ovarian morphology on ultrasound; PCOS — polycystic ovary 
syndrome
Figure 3. Mean values of free androgen index for PCOS phenotypes, 
PCOM and NOM; NOM — normal ovarian morphology; PCOM 
— polycystic ovarian morphology on ultrasound; PCOS — polycystic 
ovary syndrome
NOM vs all PCOS phenotypes p < 0.001
PCOM vs all PCOS phenotypes p < 0.001
PCOS D vs A, p < 0.001
PCOS D vs B p < 0.001
PCOS D vs C p < 0.001
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ferentiating between the phenotypes of PCOS [17, 18, 24]. 
The relation between AFC and AMH predicts that AMH val-
ues may be higher in PCOM than NOM, but in our study, se-
rum AMH values were similar for PCOM and NOM group. This 
situation shows that the increased number of 2–9 mm diam-
eter follicles, is not the only determinant of serum AMH [2]. 
LH is also involved in higher AMH production [25]. When 
granulosa cells are exposed to LH, there is an increased 
secretion of AMH in anovulatory polycystic ovaries, which 
is not seen in normal ovaries [25]. In our study group, AMH 
levels were statistically lower in PCOM patients compared 
to all phenotypes of PCOS. In our study, the most common 
PCOS phenotype was A, similar to previous studies in the 
literature [26–28]. In the current study, hyperandrogenic 
PCOS phenotypes (A, B, C) presented higher AMH levels 
as compared with normoandrogenic phenotype D. The 
highest AMH levels were observed in phenotype A which 
shows all three components of the syndrome. AMH levels 
of PCOS phenotype A were statistically significantly higher 
compared to PCOS phenotype D. Piouka et al. showed that 
anti-müllerian hormone levels indicate the severity of PCOS, 
which was negatively correlated with BMI, and they found 
that phenotype A has the highest levels of AMH [29]. In addi-
tion, Piouka et al. [29] determined that AMH concentrations 
were 65% lessened in women with high BMI compared to 
women of normal BMI and this outcome was supported by 
the study of Freeman et al. [30]. Our study group was formed 
from patients with similar mean BMIs and therefore we did 
not observe any correlation between BMI and AMH. 
In our study, the highest FAI was detected in Phenotype A, 
while the lowest value was observed in phenotype D among 
PCOS patients. There was a statistically significant difference 
in FAI between phenotype D vs other PCOS phenotypes. In 
addition, in the phenotype D group, although the mean of 
FAI was in the normal range, it was significantly higher 
than the NOM and PCOM groups. Romualdi et al. found 
a markedly difference in terms of FAI, between phenotype 
A vs phenotype D and phenotype A vs healthy controls, simi-
lar to our study findings [31]. However, in contrast with our 
results, they did not find a statistically significant difference 
between phenotype D vs phenotype B and C [31]. Polak’s 
study showed that the mean of FAI in hyperandrogenic phe-
notypes of PCOS was markedly higher than control group 
while phenotype D and control groups were similar [32]. In 
the comparison of PCOS subgroups in terms of FAI, there 
was a significant increase only in phenotype A compared 
to the phenotype D [32]. Whereas in our research, FAI was 
significantly higher in hyperandrogenic PCOS phenotypes 
(A, B, C) than in phenotype D.
Although, insulin resistance (IR) has been very popular 
in the evaluation of PCOS, it is not included in the diagnos-
tic criteria just like AMH. High insulin resistance in women 
with PCOS is considered as an alternate factor to assess the 
severity of the disease. Therefore, in most severe pheno-
type, insulin resistance is expected to be higher . We found 
that HOMA-IR values were statistically higher in all PCOS 
phenotypes compared to PCOM and NOM. Between the 
phenotypes, phenotype A had the highest HOMA-IR level, 
but this finding was not statistically significant. We can con-
duct that the HOMA-IR values have same distribution among 
the four phenotypes. Gupta et al. observed the relationship 
between insulin resistance, AMH and BMI among the four 
phenotypes of PCOS and their study results showed no dif-
ferences in terms of IR among the different phenotypes of 
PCOS [33]. About the relation between IR and AMH, there 
is no concensus with some declaring a positive correlation 
[28, 34], while others stating there is no association [27, 29], 
or a negative correlation [35]. Piouka et al. found that IR 
indexes and AMH does not have any direct link [29]. Also, 
our study outcomes did not show any correlation between 
AMH and HOMA-IR. This result may be due to our sample’s 
similar BMI values. 
The most important strength of this study is that it is 
one of the largest studies in the literature that evaluates 
serum AMH among PCOS phenotypes. The homogenous 
study population and well defined PCOS, PCOM patients 
and healthy control groups are the advantages of this work. 
Although the similar characteristics of PCOS and healthy 
groups in terms of body mass index makes the study more 
homogeneous, the lack of comparison in obese PCOS pa-
tients can be considered as the limitation of the study. The 
other limitation of the study is that it was performed retro-
spectively. Additionally, the ultrasound examinations of the 
Figure 4. Mean values of HOMA-IR for PCOS phenotypes, PCOM and 
NOM; NOM — normal ovarian morphology; PCOM — polycystic 
ovarian morphology on ultrasound
NOM vs all PCOS phenotypes p < 0.001
NOM vs PCOM p = 0.793
PCOM vs PCOS all phenotypes p < 0.001
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patients were done by different clinicians and this is another 
limitation to the study. 
CONCLUSIONS
In conclusion, according to our results, the prevalence 
of the four phenotypes of PCOS varies and Phenotype A is 
the most severe and common form. The literature shows 
controversial results on the relationship between hormo-
nal and metabolic aspects in various phenotypes. AMH 
reflects the severity of the disease with those exhibiting all 
the symptoms of PCOS. Phenotype A had the highest AMH 
levels among the PCOS phenotypes. We could not find any 
correlation between AMH levels and HOMA-IR and BMI in 
our study. 
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